Stock futures edged higher on Wednesday as Wall Street appeared to stabilize after three days of extreme swings.
S&P 500 futures were up 0.16%, Dow Jones Industrial Average futures added 0.13%, and Nasdaq rose 0.24%.
Markets have moved in a wide range over the past three days as Federal Reserve chatter left investors uncertain which way officials will vote at next week's policy meeting. Chances of an increase in interest rates this month now sit at around 15%, according to CME Group fed funds futures, after welcome dovish remarks from Fed Gov. Lael Brainard at the beginning of the week. The December meeting has higher chances at 45%.
Import and export prices in August fell with imports dragged lower by declining fuel and food costs. Import prices declined 0.2%, the first decline in six months and double the expected drop. Export prices fell 0.8%, far sharper than an anticipated 0.1% decline. Soft inflation has been one reason for the Fed's caution in raising rates.
Crude oil prices also stabilized on Wednesday, rebounding from a 3% selloff a day earlier. Prices traded in a tighter range after the latest weekly inventories data from the American Petroleum Institute and ahead of official data from the Energy Information Administration out mid-morning. API reported an increase in U.S. crude oil inventories of 1.4 million barrels.
Crude sold off a day earlier after the International Energy Agency said global demand growth was slowing by more than previously thought. The energy watchdog predicted the slowdown would continue in 2017. Commodity traders are already nervous over ballooning international supply.
West Texas Intermediate crude oil added 0.5% to $45.14 a barrel on Wednesday.
Monsanto (MON) has agreed to a $56 billion acquisition by Bayer (BAYRY) after months of negotiations. Bayer has offered $128 a share, a 21% premium to Monsanto's Tuesday close and 44% above its levels in May before the initial offer. The companies expect to receive regulatory approval by the end of next year and, in the case of rejection, Bayer will deliver a $2 billion reverse antitrust breakup fee.
Vitae Pharmaceuticals (VTAE) rocketed 157% higher in premarket trading after Allergan (AGN) agreed to acquire the pharmaceutical company in a deal worth $639 million. Allergan offered to purchase Vitae for $21 a share, a 150% premium to its Tuesday close. The deal will supplement Allergan's dermatology product line, introducing treatments for conditions such as psoriasis.
Herbalife (HLF) shares were up 2.4% in premarket trading after billionaire activist Carl Icahn disclosed that he has asked the Federal Trade Commission for the right to buy up to 50% of the supplements maker. Icahn said he is considering delivering a tender offer in comments made to CNBC's Delivering Alpha conference on Tuesday. Icahn already has permission to buy up to 35% while hedge fund manager Bill Ackman, of Pershing Square Capital, expects the company's shares to wither and has built up a short position.
Ford (F) slipped 0.5% in premarket trading after detailing plans to invest in electric and self-driving vehicles over the next several years. The automaker plans to pony up $4.5 billion in research and development towards electric car development by 2020, according to a presentation prepared ahead of its investment day. A fully-autonomous vehicle for use in ride-sharing services is expected to be in commercial production by 2021.
Speculation over the outcome of next week's Fed meeting will be rife in the coming days with little in the way of new information on which to trade. No Fed members are left to speak this week, few companies of note are set to report, save Oracle (ORCL) on Thursday, and economic data such as producer and consumer prices and retail sales are crammed into a busy Thursday and Friday.
September is historically the worst-performing month for stocks with seasonal factors such as light trading volumes and a general wariness over historical trading patterns. The Dow has fallen an average 1.1% in September since the benchmark index was created in 1896, compared to an average gain of 0.8% over the remaining 11 months.